

INNOVATIVE VISION PRODUCTS, INC.

Delaware Office:

3511 Silverside Road, Suite 105,
County of New Castle,
Delaware USA 19810
markbabizhayev@yahoo.com

Moscow Office:

Ivanovskaya 20, Suite 74,
Moscow 127434
Russia
Tel/Fax: +7 495 977 2387

<http://www.innovative-vision-products.com>

GLOBAL VISION

New worldwide patented IVP oral Healthcare Product on the US and European Markets:

(WO 2004/028536 A1; WO 94/19325; WO 95/12581; WO 2004/064866 A1)



Can-C Plus 60 caps	Item Code: 0629
<p>Can-C Plus helps to enhance free radical protection and reduce the oxidative environment inside the eye. In addition, Can-C Plus helps prevent the carnosine in the eye-drops from being broken down; this action increases both the potency of the eye-drops and the length of time that the eye-drops remain active in the eye.</p> <p><u>60 Caps</u></p>	

Innovative Vision Products Inc. is a Pharmaceutical and Nanotechnology

Development Company with a focus on innovative chemical entities, drug delivery systems, and unique medical devices to target specific biomedical applications. Over the last decade IVP has developed a track record in developing these technologies to effectively address the unmet needs of specific diseased populations.



Can-C Plus™ the NEW ultimate oral supplement for eye protection

For quite a while we have been looking for the right oral formula to be used along with Can-C eye-drops. The problem has been that a number of popular eye supplement contain lutein and astaxanthin and they compete with the receptors in the eye with the n-acetylcarnosine. Whilst this is not “dangerous” it can mean that the efficacy of the eye-drops is reduced. This is problematic because the “star” of the show is the n-acetylcarnosine and the first priority is to deliver this effectively.

So we are now delighted that a unique, new and patented formula has been developed by IVP, (the inventors of Can-C). The new formula is called Can-C Plus and its synergistic combination of ingredients provides an environment for Can-C eye drops to be even more beneficial.

Can-C Plus helps to enhance free radical protection and reduce the oxidative environment inside the eye. In addition, Can-C Plus helps prevent the carnosine in the eye-drops from being broken down; this action increases both the potency of the eye-drops and the length of time that the eye-drops remain active in the eye.

We recommend Can-C Plus for those who:

- (a) Want the maximum benefit from day one and thus take 1 capsule of Can-C Plus two or three times daily along with the Can-C eye-drops.
- (b) Those who have very dense cataract and severely diminished vision to start with should combine the capsules with the eye-drops from day one. This will give the best environment for the eye-drops and thus to give the best results they can achieve within 5 to 6 months.
- (c) Or those who are budget conscious can extend the efficiency of the eye-drops by adding the capsules to the regime after 5-months of applying the eye-drops by themselves first.

Cataract Patients Benefit From Improved Vision Care with N-acetylcarnosine Lubricant Eye Drops and Nutritional Supplement Containing Amino Acid Compounds with Synergistic Activity

Synergism of histidyl dipeptides and amino acids as antioxidants in ophthalmic treatments

Since there is a range of the histidyl dipeptides within mammalian tissues we have investigated possible synergism between them in respect of antioxidant activity in ophthalmic treatments. The efficacy of N-acetylcarnosine eye drops in the therapeutic treatment of ripe cataracts, reduction in visual acuity and in addition, the management of 'halo' effects and vitreous lesions (including floaters) may also be contributed by non-enzymatic antioxidants such as reduced glutathione.

In a separate pilot study the treatment of a ripe human age-related cataract during 5 months with patented N-acetylcarnosine lubricant eye drops (twice daily instillations) was combined with the worldwide patented by Dr. Babizhayev/IVP and the allied Groups unique Oral Healthcare supplement formulation Can-C Plus applied with an oral therapeutic regimen (treated with a daily per oral dose of three capsules)

Manipulation with chemical chaperones N-acetylcarnosine, carnosine, D-pantethine or regulated/inducible molecular chaperone protein function (such as alpha-crystallin chaperone activity in the lens) might offer potential novel therapies for reversal of (ripe) cataracts, retinal degeneration and ocular complications of diabetes. The Can-C Plus oral product combined

with daily administration of 1% n-acetylcarnosine lubricant eye drops significantly decreases the parameters of intraocular pressure and improves visual functions in primary open-angle glaucoma (POAG) patients.

L-Histidine ingredient is acting synergistically with other natural imidazole-containing Peptidomimetics (N-acetylcarnosine, L-carnosine) as antioxidant. Since there is a range of these imidazole dipeptides/peptidomimetics within mammalian tissue(s) we have investigated possible synergism between them in respect of antioxidant activity. Our results show that combining imidazole-containing compounds at near physiological concentrations results in synergistic antioxidant activity.

The oral consumption of N-acetylcysteine ingredient boosts the reduced glutathione level in the human crystalline lens. As indicated in the Figure, ripe age-related cataract is significantly reversed within 5 months of combined treatment. The clinical and experimental data demonstrate the effectiveness and safety of a combined treatment modality.




Figure . In a separate pilot study the treatment of a ripe human age-related cataract during 5 months with patented N-acetylcarnosine lubricant eye drops (twice daily instillations) was combined with the worldwide patented by Dr. Babizhayev/IVP and the allied Groups unique Oral Healthcare supplement formulation Can-C Plus applied with an oral therapeutic regimen (treated with a daily per oral dose of two capsules) (WO 2004/028536 A1; WO 94/19325; WO 95/12581; WO 2004/064866 A1). Left image: pronounced opacities in the lens layers prior cataract treatment; Right image: An appearance of the rose reflex visible through the lens which became significantly more transparent after 5 months of combined treatment of cataract with the N-acetylcarnosine eye drop combined with oral supplement Can-C Plus.

Please, contact IVP directly for the promotional issues of Can-C Plus at the territories of interest.

Cordially,

Dr. Mark A. Babizhayev, Executive Director

References :

1.

[State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatment and therapeutic management of a group of sight-threatening eye diseases.](#)

Babizhayev MA, Kasus-Jacobi A.

Curr Clin Pharmacol. 2009 Jan;4(1):4-37.

PMID: 19149498 [PubMed - in process]

[Related Articles](#)

□ **2:**

[N-Acetylcarnosine and histidyl-hydrazide are potent agents for multitargeted ophthalmic therapy of senile cataracts and diabetic ocular complications.](#)

Babizhayev MA, Guiotto A, Kasus-Jacobi A.

J Drug Target. 2009 Jan;17(1):36-63.

PMID: 19037813 [PubMed - in process]

[Related Articles](#)

□ **3:**

[Cataract halos: a driving hazard in aging populations. Implication of the Halometer DG test for assessment of intraocular light scatter.](#)

Babizhayev MA, Minasyan H, Richer SP.

Appl Ergon. 2009 May;40(3):545-53. Epub 2008 Sep 24.

PMID: 18814857 [PubMed - in process]

[Related Articles](#)

4:

[Ocular drug metabolism of the bioactivating antioxidant N-acetylcarnosine for vision in ophthalmic prodrug and codrug design and delivery.](#)

Babizhayev MA.

Drug Dev Ind Pharm. 2008 Oct;34(10):1071-89.

PMID: 18777243 [PubMed - indexed for MEDLINE]

[Related Articles](#)

5:

[Malondialdehyde scavenging and aldose-derived Schiff bases' transglycation properties of synthetic histidyl-hydrazide carnosine analogs.](#)

Guiotto A, Ruzza P, Babizhayev MA, Calderan A.

Bioorg Med Chem. 2007 Sep 15;15(18):6158-63. Epub 2007 Jun 20.

PMID: 17604632 [PubMed - indexed for MEDLINE]

[Related Articles](#)

6:

[Biological activities of the natural imidazole-containing peptidomimetics n-acetylcarnosine, carbinine and L-carnosine in ophthalmic and skin care products.](#)

Babizhayev MA.

Life Sci. 2006 Apr 11;78(20):2343-57. Epub 2006 Jan 4.

PMID: 16388826 [PubMed - indexed for MEDLINE]

[Related Articles](#)

7:

[Analysis of lipid peroxidation and electron microscopic survey of maturation stages during human cataractogenesis: pharmacokinetic assay of Can-C N-acetylcarnosine prodrug lubricant eye drops for cataract prevention.](#)

Babizhayev MA.

Drugs R D. 2005;6(6):345-69.

PMID: 16274259 [PubMed - indexed for MEDLINE]

[Related Articles](#)

8:

[3D molecular modeling, free radical modulating and immune cells signaling activities of the novel peptidomimetic L-glutamyl-histamine: possible immunostimulating role.](#)

Babizhayev MA, Semiletov YA, Lul'kin YA, Sakina NL, Savel'yeva EL, Alimbarova LM, Barinskii IP.

Peptides. 2005 Apr;26(4):551-63. Epub 2004 Dec 29.

PMID: 15752568 [PubMed - indexed for MEDLINE]

[Related Articles](#)

9:

[Immunostimulating activities of the novel peptidomimetic L-glutamyl-histamine.](#)

Babizhayev MA, Semiletov YA, Lul'kin YA, Sakina NL, Savel'yeva EL, Alimbarova LM, Barinskii IP.

Clin Exp Immunol. 2005 Mar;139(3):447-57.

PMID: 15730390 [PubMed - indexed for MEDLINE]

[Related Articles](#) [Free article in PMC](#) | [at journal site](#)

10:

[Rejuvenation of visual functions in older adult drivers and drivers with cataract during a short-term administration of N-acetylcarnosine lubricant eye drops.](#)

Babizhayev MA.

Rejuvenation Res. 2004 Fall;7(3):186-98.

PMID: 15588519 [PubMed - indexed for MEDLINE]

[Related Articles](#)

11:

[Lipid peroxidation and cataracts: N-acetylcarnosine as a therapeutic tool to manage age-related cataracts in human and in canine eyes.](#)

Babizhayev MA, Deyev AI, Yermakova VN, Brikman IV, Bours J.

Drugs R D. 2004;5(3):125-39. Review.

PMID: 15139774 [PubMed - indexed for MEDLINE]

[Related Articles](#)

12:

[Hydration properties of the molecular chaperone alpha-crystallin in the bovine lens.](#)

Babizhayev MA, Nikolayev GM, Goryachev SN, Bours J, Martin R.

Biochemistry (Mosc). 2003 Oct;68(10):1145-55.

PMID: 14616086 [PubMed - indexed for MEDLINE]

[Related Articles](#)

13:

[Image analysis and glare sensitivity in human age-related cataracts.](#)

Babizhayev MA, Deyev AI, Yermakova VN, Davydova NG, Kurysheva NI, Doroshenko VS, Zhukotskii AV.

Clin Exp Optom. 2003 May;86(3):157-72.

PMID: 12767250 [PubMed - indexed for MEDLINE]

[Related Articles](#)

14:

[Glare disability and driving safety.](#)

Babizhayev MA.

Ophthalmic Res. 2003 Jan-Feb;35(1):19-25.

PMID: 12566859 [PubMed - indexed for MEDLINE]

[Related Articles](#)

15:

[NMR spin-echo studies of hydration properties of the molecular chaperone alpha-crystallin in the bovine lens.](#)

Babizhayev MA, Nikolayev GN, Goryachev SN, Bours J.

Biochim Biophys Acta. 2002 Jul 29;1598(1-2):46-54.

PMID: 12147343 [PubMed - indexed for MEDLINE]

[Related Articles](#)

16:

[Efficacy of N-acetylcarnosine in the treatment of cataracts.](#)

Babizhayev MA, Deyev AI, Yermakova VN, Semiletov YA, Davydova NG, Doroshenko VS, Zhukotskii AV, Goldman IM.

Drugs R D. 2002;3(2):87-103.

PMID: 12001824 [PubMed - indexed for MEDLINE]

[Related Articles](#)

□ **17:**

[N-Acetylcarnosine, a natural histidine-containing dipeptide, as a potent ophthalmic drug in treatment of human cataracts.](#)

Babizhayev MA, Deyev AI, Yermakova VN, Semiletov YA, Davydova NG, Kuryshева NI, Zhukotskii AV, Goldman IM.

Peptides. 2001 Jun;22(6):979-94.

PMID: 11390029 [PubMed - indexed for MEDLINE]

[Related Articles](#)

□ **18:**

[The natural histidine-containing dipeptide Nalpha-acetylcarnosine as an antioxidant for ophthalmic use.](#)

Babizhayev MA, Yermakova VN, Semiletov YA, Deyev AI.

Biochemistry (Mosc). 2000 May;65(5):588-98.

PMID: 10851037 [PubMed - indexed for MEDLINE]

[Related Articles](#)

□ **19:**

[Cellular signalling and free-radical modulating activities of the novel peptidomimetic L-glutamyl-histamine.](#)

Babizhayev MA, Semiletov YA, Lul'kin YA, Sakina NL, Savel'yeva EL, Deyev AI, Alimbarova LI, Barinskii IF, Nicolay J, Paillet C, Langrand G, Seguin F.

Biochemistry (Mosc). 1999 May;64(5):510-22.

PMID: 10381611 [PubMed - indexed for MEDLINE]

[Related Articles](#)

□ **20:**

[Photoprotector and antioxidant properties of histamine-containing peptidomimetics in the photooxidation of glycytryptophan.](#)

Babizhayev MA, Lozovskaya EL, Makareyeva EN, Lul'kin YA, Sapezhinskii II.

Biochemistry (Mosc). 1998 May;63(5):523-8.

PMID: 9632886 [PubMed - indexed for MEDLINE]

[Related Articles](#)

